RO7656594 for Advanced or Metastatic Prostate Cancer
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
- Age
- 18 and older
- Sex
- Male
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 210 (estimated)
- Sponsor
- Genentech, Inc. · Industry
This trial is looking for men with advanced or metastatic prostate cancer. Participants will receive a study treatment called RO7656594, and the trial will check how safe it is and how well it works.
You may be able to join if
- I have metastatic prostate cancer.
- I have had treatment with second-generation androgen receptor therapies.
- I have had prior treatment with a taxane regimen or refused it.
- I have a known BRCA1 or BRCA2 mutation and had treatment with a PARP inhibitor.
You may not be able to join if
- I have had any approved anti-cancer therapy in the last 14 days.
- I have used any investigational agent in the last 28 days.
- I have treated with any previous AR protein degrader.
- I have untreated central nervous system metastases.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThe purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary activity of RO7656594 in participants with advanced or metastatic prostate cancer. It will also identify recommended doses and regimens for RO7656594 for subsequent studies.
Loading trial locations…
GO44537 https://forpatients.roche.com/ No attachments to email below.
888-662-6728 (U.S. Only)
global-roche-genentech-trials@gene.com
CONTACT
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
CONTACT